Company intelligence / Profile preview
Toragen, Inc.
- Ownership
- Private
- Development stage
- Phase 1
Overview
The company’s lead candidate TGN-S11 has entered a Phase I clinical trial in patients with relapsed or metastatic HPV-related cancers. Early results show no safety concerns across the first three dose cohorts; one-third of subjects experienced tumor size reduction and decreased circulating tumor HPV DNA. Combination studies with Keytruda are planned in the next phase.[1][2][5]
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (e.g., TGN-S11 and TGN-S15)[1][2]Immunotherapy (combination with checkpoint inhibitors like Keytruda)[1][5]
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Toragen, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Toragen, Inc..